Major drugmaker loses $27 billion in market value after failed trial

🇺🇸 MarketWatch (US) —

AI Summary

A major pharmaceutical company lost $27 billion in market value following the failure of its heart disease drug in a Phase III clinical trial. The setback has caused significant investor concern and market impact.

Two companies announced on Thursday that the heart disease drug they had been developing failed its Phase III trial.

Markets Deals Health pharmaceutical clinical trial failure market value loss heart disease drug investors

Read original source →